NeuroVive to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
Lund, Sweden, September 7, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the company is scheduled to present at the Rodman & Renshaw 18th Annual Global Investment Conference held September 11-13, 2016 in New York, US. During the presentation, an update regarding NeuroVive's research and development programs will be provided.
The presentation will include the clinical phase II projects related to acute kidney injury (AKI) prevention and treatment of traumatic brain injury (TBI). Also, the pre-clinical project NVP015 targeting genetic mitochondrial disorders will be presented (recently presented in Nature Communications).
The presentation will take place on September 13, at 5:05 p.m. EDT /11:05 p.m. CEST. The audio and slide presentation will be webcasted live and can be accessed via the NeuroVive web site. To access the live and replay presentations please go to http://www.neurovive.com/en/investor/company-presentations/ .
About NeuroVive
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) is a pioneer in mitochondrial medicine and a company committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of significant therapeutic need. NeuroVive's business approach is driven by value-adding partnerships with mitochondrial research institutions and commercial partners across the globe.
NeuroVive's portfolio consists of two clinical projects, one in acute kidney injury (CicloMulsion®) and one in traumatic brain injury (NeuroSTAT®). The candidate drug NeuroSTAT has orphan drug designation in Europe and in the US for treatment of moderate to severe traumatic brain injury and is currently being evaluated in the CHIC study. CicloMulsion is being evaluated in an on-going study, CiPRICS, in acute kidney injury during major surgery. Furthermore, the R&D portfolio consists of two late stage discovery programs and one compound in preclinical development.
NeuroVive is listed on Nasdaq Stockholm, Sweden, Small Cap, under the ticker symbol NVP. The share is also traded on the OTC Markets Group Inc market in the US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTCQX Best Market.
For investor relations and media questions, please contact:
Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
www.neurovive.com
This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 02:00 p.m. CEST on Sep 7, 2016.